Barclays PLC Purchases 144,883 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Barclays PLC grew its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 496.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 174,061 shares of the company’s stock after buying an additional 144,883 shares during the period. Barclays PLC owned 0.33% of Janux Therapeutics worth $7,907,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of New York Mellon Corp boosted its stake in Janux Therapeutics by 136.3% during the second quarter. Bank of New York Mellon Corp now owns 115,027 shares of the company’s stock worth $4,818,000 after acquiring an additional 66,340 shares in the last quarter. Summit Securities Group LLC purchased a new stake in shares of Janux Therapeutics in the 2nd quarter worth approximately $29,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Janux Therapeutics during the 2nd quarter valued at approximately $151,000. Principal Financial Group Inc. purchased a new position in Janux Therapeutics during the second quarter valued at $237,000. Finally, Rhumbline Advisers boosted its holdings in Janux Therapeutics by 41.2% in the second quarter. Rhumbline Advisers now owns 38,008 shares of the company’s stock worth $1,592,000 after acquiring an additional 11,085 shares in the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, major shareholder Ventures Xi L.P. Avalon sold 49,231 shares of the business’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $46.45, for a total transaction of $2,286,779.95. Following the completion of the sale, the insider now owns 6,926 shares of the company’s stock, valued at $321,712.70. The trade was a 87.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Andrew Hollman Meyer sold 50,000 shares of the company’s stock in a transaction on Friday, September 27th. The stock was sold at an average price of $45.96, for a total value of $2,298,000.00. Following the completion of the sale, the insider now owns 67,592 shares of the company’s stock, valued at $3,106,528.32. This trade represents a 42.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 192,032 shares of company stock valued at $9,512,515 in the last quarter. 29.40% of the stock is currently owned by insiders.

Janux Therapeutics Trading Down 3.2 %

Shares of JANX opened at $59.61 on Wednesday. The firm has a fifty day simple moving average of $53.37 and a two-hundred day simple moving average of $46.92. The firm has a market cap of $3.13 billion, a PE ratio of -50.95 and a beta of 3.29. Janux Therapeutics, Inc. has a 1-year low of $7.79 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. The firm’s quarterly revenue was down 82.6% compared to the same quarter last year. As a group, research analysts forecast that Janux Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on JANX. Cantor Fitzgerald restated an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a report on Wednesday, December 11th. Stifel Nicolaus raised their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research report on Tuesday, December 3rd. Finally, HC Wainwright upped their price objective on Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $89.90.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.